S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
Biden To Unleash "Choke Point" Operation On America? (Ad)
Closing prices for crude oil, gold and other commodities
KB Home Strong Results Lift Prices
Biden To Unleash "Choke Point" Operation On America? (Ad)
Trump arrested? Putin jailed? Fake AI images spread online
These 3 Chip Stocks May Be Approaching A Buy Point Soon
Biden To Unleash "Choke Point" Operation On America? (Ad)
Lawsuit: Slurs, coercion at BBQ chain with racist history
Coinbase tumbles after SEC warns of securities violations
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
Biden To Unleash "Choke Point" Operation On America? (Ad)
Closing prices for crude oil, gold and other commodities
KB Home Strong Results Lift Prices
Biden To Unleash "Choke Point" Operation On America? (Ad)
Trump arrested? Putin jailed? Fake AI images spread online
These 3 Chip Stocks May Be Approaching A Buy Point Soon
Biden To Unleash "Choke Point" Operation On America? (Ad)
Lawsuit: Slurs, coercion at BBQ chain with racist history
Coinbase tumbles after SEC warns of securities violations
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
Biden To Unleash "Choke Point" Operation On America? (Ad)
Closing prices for crude oil, gold and other commodities
KB Home Strong Results Lift Prices
Biden To Unleash "Choke Point" Operation On America? (Ad)
Trump arrested? Putin jailed? Fake AI images spread online
These 3 Chip Stocks May Be Approaching A Buy Point Soon
Biden To Unleash "Choke Point" Operation On America? (Ad)
Lawsuit: Slurs, coercion at BBQ chain with racist history
Coinbase tumbles after SEC warns of securities violations
S&P 500   3,948.72
DOW   32,105.25
QQQ   309.75
Chewy Stock Is Setting Up For Long-Term Profitable Growth 
Biden To Unleash "Choke Point" Operation On America? (Ad)
Closing prices for crude oil, gold and other commodities
KB Home Strong Results Lift Prices
Biden To Unleash "Choke Point" Operation On America? (Ad)
Trump arrested? Putin jailed? Fake AI images spread online
These 3 Chip Stocks May Be Approaching A Buy Point Soon
Biden To Unleash "Choke Point" Operation On America? (Ad)
Lawsuit: Slurs, coercion at BBQ chain with racist history
Coinbase tumbles after SEC warns of securities violations
NASDAQ:MBRX

Moleculin Biotech - MBRX Competitors

$0.94
-0.09 (-8.71%)
(As of 03/23/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.93
$1.02
50-Day Range
$0.94
$1.34
52-Week Range
$0.82
$2.05
Volume
111,442 shs
Average Volume
76,805 shs
Market Capitalization
$27.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.50

MBRX vs. IMMX, LPCN, KALA, SIOX, NOVN, CPIX, STSA, NLTX, CRBP, and LUMO

Should you be buying Moleculin Biotech stock or one of its competitors? The main competitors of Moleculin Biotech include Immix Biopharma (IMMX), Lipocine (LPCN), Kala Pharmaceuticals (KALA), Sio Gene Therapies (SIOX), Novan (NOVN), Cumberland Pharmaceuticals (CPIX), Satsuma Pharmaceuticals (STSA), Neoleukin Therapeutics (NLTX), Corbus Pharmaceuticals (CRBP), and Lumos Pharma (LUMO). These companies are all part of the "pharmaceutical preparations" industry.

Moleculin Biotech vs.

Moleculin Biotech (NASDAQ:MBRX) and Immix Biopharma (NASDAQ:IMMX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, community ranking, institutional ownership, media sentiment, analyst recommendations, dividends, earnings and profitability.

Moleculin Biotech has a beta of 2.03, suggesting that its stock price is 103% more volatile than the S&P 500. Comparatively, Immix Biopharma has a beta of -0.06, suggesting that its stock price is 106% less volatile than the S&P 500.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Moleculin BiotechN/AN/A-$15.89 million-$1.02-0.92
Immix BiopharmaN/AN/A-$24.38 millionN/AN/A

Moleculin Biotech's return on equity of -39.62% beat Immix Biopharma's return on equity.

Company Net Margins Return on Equity Return on Assets
Moleculin Biotech N/A -39.62% -36.32%
Immix Biopharma N/A -149.98% -145.58%

Moleculin Biotech presently has a consensus price target of $10.50, suggesting a potential upside of 1,013.35%. Immix Biopharma has a consensus price target of $14.00, suggesting a potential upside of 610.66%. Given Moleculin Biotech's higher probable upside, research analysts plainly believe Moleculin Biotech is more favorable than Immix Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Moleculin Biotech
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Immix Biopharma
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Moleculin Biotech received 219 more outperform votes than Immix Biopharma when rated by MarketBeat users. However, 100.00% of users gave Immix Biopharma an outperform vote while only 60.33% of users gave Moleculin Biotech an outperform vote.

CompanyUnderperformOutperform
Moleculin BiotechOutperform Votes
222
60.33%
Underperform Votes
146
39.67%
Immix BiopharmaOutperform Votes
3
100.00%
Underperform Votes
No Votes

In the previous week, Moleculin Biotech had 6 more articles in the media than Immix Biopharma. MarketBeat recorded 7 mentions for Moleculin Biotech and 1 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 1.90 beat Moleculin Biotech's score of -0.32 indicating that Immix Biopharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Moleculin Biotech
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Immix Biopharma
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

10.4% of Moleculin Biotech shares are held by institutional investors. Comparatively, 2.2% of Immix Biopharma shares are held by institutional investors. 3.7% of Moleculin Biotech shares are held by insiders. Comparatively, 51.3% of Immix Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Moleculin Biotech beats Immix Biopharma on 8 of the 12 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MBRX vs. The Competition

MetricMoleculin BiotechPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$27.00M$5.58B$4.33B$5.87B
Dividend YieldN/A2.59%2.39%4.45%
P/E Ratio-1.089.48153.8415.58
Price / SalesN/A291.023,554.6666.15
Price / CashN/A19.3626.80101.17
Price / Book0.344.194.474.95
Net Income-$15.89M$187.08M$115.27M$190.96M
7 Day Performance-3.77%-1.47%-1.04%0.21%
1 Month Performance-25.15%-8.75%-6.86%-6.24%
1 Year Performance-47.61%-15.63%-16.83%-19.14%

Moleculin Biotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMMX
Immix Biopharma
1.6852 of 5 stars
$2.14
+12.0%
$14.00
+554.2%
-4.4%$29.81MN/A0.002Upcoming Earnings
News Coverage
Positive News
LPCN
Lipocine
1.8789 of 5 stars
$0.33
flat
$4.00
+1,120.3%
-82.8%$29.01M$500,000.00-2.3413Gap Up
KALA
Kala Pharmaceuticals
2.2082 of 5 stars
$14.17
-6.5%
$51.13
+260.8%
-61.5%$28.77M$3.89M-0.47192
SIOX
Sio Gene Therapies
1.6729 of 5 stars
$0.42
+2.5%
$0.80
+92.8%
-40.7%$30.27MN/A0.0042High Trading Volume
NOVN
Novan
1.8386 of 5 stars
$1.24
+4.2%
$14.50
+1,069.4%
-68.1%$30.33M$2.96M-0.6729Upcoming Earnings
CPIX
Cumberland Pharmaceuticals
0 of 5 stars
$1.94
-1.5%
N/A-30.5%$28.36M$42.01M-5.1183Analyst Report
Gap Down
STSA
Satsuma Pharmaceuticals
2.2868 of 5 stars
$0.85
flat
$7.40
+770.5%
-77.3%$28.16MN/A-0.4321Gap Down
NLTX
Neoleukin Therapeutics
2.1166 of 5 stars
$0.66
-1.5%
$6.00
+809.1%
-64.9%$28.10MN/A-0.6191Analyst Revision
News Coverage
Gap Down
CRBP
Corbus Pharmaceuticals
1.5623 of 5 stars
$6.66
+4.2%
$3.00
-55.0%
+1,258.6%$27.77M$880,000.00-0.6441
LUMO
Lumos Pharma
2.1743 of 5 stars
$3.34
+3.4%
$17.67
+428.9%
-66.3%$27.46M$1.52M-0.9029Gap Up
This page (NASDAQ:MBRX) was last updated on 3/24/2023 by MarketBeat.com Staff